Marinus Pharmaceuticals Inc (MRNS)

[Titan V]

Red flags in the data set will probably only become relevant when brexanolone reaches the market and has to compete with other options. True, there is nothing specifically approved to treat the condition, though various anti-depressants are prescribed. But that could change in the near future – Marinus Pharmaceuticals is due to start reporting data from its phase II postpartum depression programme early next year, with a similar agent called ganaxolone. Shares in the company opened 17% higher today on hopes for comparable success.

Results from Marinus will be held up against the data below, which shows that Sage delivered a stronger placebo-adjusted reading in patients with more severe depression. These patients also demonstrated a sustained, significant effect through a 30-day follow up period; a statistically significant difference in effect size was not seen over 30 days in moderate patients.

http://www.epvantage.com/Universal/View.aspx?type=Story&id=745778&isEPVantage=yes